Sign in
TerminatedPhase 1

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

Key facts

Who runs it
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
192 people enrolled
Started
9 Jun 2021
Ended
30 Dec 2025
Type of study
Interventional
Treatments tested
  • TQB3720
Record updated
31 March 2026
Why it stopped
Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.

Who can take part

Age
18 years to 80 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • 1. Histologically or cytologically confirmed prostate carcinoma. 2.Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2; Life expectancy ≥12 weeks; 3.Testosterone levels < 50 ng/dL. 4. Has received ≥1 previous regimens for metastatic castration-resistant prostate cancer; 5.Male subjects should agree to use an adequate method of contraception starting with signing ICF through 6 months after the last dose of study; 6.Understood and signed an informed consent form

Who cannot take part

  • -1.Has symptomatic brain metastases or control of symptoms < 1 month. 2.Has other malignancies within 3 years. 3.Has used second-generation androgen receptor antagonists. 4. Abnormal liver function. 5. Abnormal renal function. 6. Has received any other investigational drug within 30 days weeks before first dose
  • According to the judgement of the researchers, there are other factors that subjects are not suitable for the study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is conducted to investigate the pharmacokinetic and safety profiles of TQB3720 in patients with metastatic castration-resistant prostate cancer.

The group in the trial

  • TQB3720 tabletsTreatment being tested

    TQB3720 tablets administered orally, once daily in 28-day cycle.

    Treatment: TQB3720

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets
Record updated
31 March 2026